Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marius M Hoeper

Showing results (181-190 of 311) with videos related to

Pageof 32
Sort By:
The American Journal of Pathology|June 28, 2011
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironmentDanny Jonigk, Heiko Golpon, Clemens L Bockmeyer, et al.
Critical Care (London, England)|March 4, 2011
Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infectionGernot Beutel, Olaf Wiesner, Matthias Eder, et al.
Infection|November 4, 2023
Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19Isabell Pink, Jan K Hennigs, Louisa Ruhl, et al.
Frontiers in Psychiatry|May 2, 2022
Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial HypertensionFlora Caldarone, Philippa Gebhardt, Marius M Hoeper, et al.
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Plos One|November 2, 2022
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Theresa Kirchner, Sophia Heinrich, Agnes Bonifacius, et al.
Advances in Therapy|November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard Channick, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 8, 2018
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trialJean-Luc Vachiéry, Nazzareno Galiè, Joan Albert Barberá, et al.
Respiratory Research|September 13, 2019
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertensionR James White, Anton Vonk-Noordegraaf, Stephan Rosenkranz, et al.
International Journal of Cardiology|May 29, 2020
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITERaymond L Benza, Paul A Corris, James R Klinger, et al.
Pageof 32

Showing results (181-190 of 311) with videos related to

Sort By:
Pageof 32
The American Journal of Pathology|June 28, 2011
Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironmentDanny Jonigk, Heiko Golpon, Clemens L Bockmeyer, et al.
Critical Care (London, England)|March 4, 2011
Virus-associated hemophagocytic syndrome as a major contributor to death in patients with 2009 influenza A (H1N1) infectionGernot Beutel, Olaf Wiesner, Matthias Eder, et al.
Infection|November 4, 2023
Blood T cell phenotypes correlate with fatigue severity in post-acute sequelae of COVID-19Isabell Pink, Jan K Hennigs, Louisa Ruhl, et al.
Frontiers in Psychiatry|May 2, 2022
Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial HypertensionFlora Caldarone, Philippa Gebhardt, Marius M Hoeper, et al.
European Journal of Heart Failure|November 22, 2021
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON studyStephan Rosenkranz, Richard Channick, Kelly M Chin, et al.
Plos One|November 2, 2022
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Theresa Kirchner, Sophia Heinrich, Agnes Bonifacius, et al.
Advances in Therapy|November 2, 2021
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label ExtensionNazzareno Galiè, Sean Gaine, Richard Channick, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 8, 2018
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trialJean-Luc Vachiéry, Nazzareno Galiè, Joan Albert Barberá, et al.
Respiratory Research|September 13, 2019
Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertensionR James White, Anton Vonk-Noordegraaf, Stephan Rosenkranz, et al.
International Journal of Cardiology|May 29, 2020
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITERaymond L Benza, Paul A Corris, James R Klinger, et al.
Pageof 32